In April 2024, Vincerx presented positive preliminary phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting. The VIP236 data demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors. Additionally, the VIP943 pharmacokinetic (PK) data showed very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically. Read BioWorld’s coverage on this data announcement.
